COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Low Dose Human Chorionic Gonadotropin: Influence on the Endometrium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00976651
Recruitment Status : Completed
First Posted : September 14, 2009
Last Update Posted : March 25, 2010
Information provided by:
Universitair Ziekenhuis Brussel

Brief Summary:
The purpose of the present study is to assess the influence of the administration of low dose hCG on the endometrium. The study is a randomised trial where 2 groups of patients, undergoing a gonadotropin-releasing hormone antagonist protocol for in vitro fertilization, are studied. In addition to the histological findings, by analysing the correlation of the morphological pattern and gene expression profile of human endometrium on the day of oocyte retrieval in patients of both treatment groups, the investigators want to study the implantation potential.

Condition or disease Intervention/treatment Phase
Infertility Drug: human menopausal gonadotropin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Influence of Ovarian Stimulation With 200 IU of hCG, (Administered in the Late Follicular Phase Among ICSI Patients Undergoing a GnRH-antagonist Protocol), on the Endometrium on the Day of Oocyte Pick-up
Study Start Date : January 2009
Actual Primary Completion Date : November 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Active Comparator: Recombinant FSH
Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
Drug: human menopausal gonadotropin
200 IU per day in the late follicular phase

Experimental: human chorionic gonadotropin

Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.

Histology and gene expression is studied on the endometrium

Drug: human menopausal gonadotropin
200 IU per day in the late follicular phase

Primary Outcome Measures :
  1. number of oocytes [ Time Frame: 2 weeks after start of the treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 36 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • < 36 years on day of randomisation
  • FSH < 12 in the early follicular phase
  • Normal ultrasound scan
  • BMI between 18 and 29 (both inclusive)
  • Randomisation at outpatient clinic

Exclusion Criteria:

  • Endometriosis ≥ grade 3
  • PCO syndrome
  • Poor responder
  • Endocrine or metabolic abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00976651

Layout table for location information
UZ Brussel
Laarbeeklaan 101, Brussels, Belgium, 1090
Sponsors and Collaborators
Universitair Ziekenhuis Brussel
Publications of Results:
Layout table for additonal information
Responsible Party: Paul Devroey, Universitair Ziekenhuis Brussel Identifier: NCT00976651    
Other Study ID Numbers: CBLD2
First Posted: September 14, 2009    Key Record Dates
Last Update Posted: March 25, 2010
Last Verified: September 2009
Keywords provided by Universitair Ziekenhuis Brussel:
infertility treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs